2022
Thrombosis questions from the inpatient wards
Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.Peer-Reviewed Original ResearchConceptsCancer-associated thrombosisInpatient wardsPurpura fulminansIntermediate-dose anticoagulationEtiology of thrombocytopeniaMajor clinical trialsCases of thrombosisCoronavirus disease 2019Recent prospective dataCOVID-19Antithrombin replacementAnticoagulation therapyAntiplatelet therapyAntithrombotic therapyAnticoagulation managementMicrovascular thrombosisPlasma transfusionHospitalized patientsAntiplatelet agentsThromboembolic diseasePlatelet countConsensus guidelinesProspective dataClinical trialsDisease 2019COVID-19 and antiphospholipid antibodies
Butt A, Erkan D, Lee A. COVID-19 and antiphospholipid antibodies. Best Practice & Research Clinical Haematology 2022, 35: 101402. PMID: 36494152, PMCID: PMC9568270, DOI: 10.1016/j.beha.2022.101402.Peer-Reviewed Original ResearchConceptsAntiphospholipid antibodiesCOVID-19 patientsAntiphospholipid syndromeCOVID-19Antiphospholipid antibody productionCOVID-19 coagulopathyCOVID-19 shareMechanism of thrombogenesisCOVID-19 vaccinationNeutrophil extracellular trapsActivation of plateletsPathophysiologic featuresClinical outcomesExtracellular trapsSuch antibodiesAntibody productionComplement pathwayPatientsSyndromeAntibodiesConflicting resultsCoagulopathyImmunothrombosisHypercoagulabilityVaccination
2021
Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis
Madeeva D, Borges K, Shallow M, Juthani P, Wang S, Gupta A, Chun H, Lee A, Pine A. Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis. Blood 2021, 138: 777. PMCID: PMC8701622, DOI: 10.1182/blood-2021-153959.Peer-Reviewed Original ResearchSerum amyloid ACOVID-19 patientsVenous thromboembolismCOVID-19 infectionLipocalin-2Thromboembolic eventsThromboembolic complicationsPentraxin 3Complement factors C2COVID-19Lower extremity Doppler ultrasoundTissue factorComplement activationCell adhesion molecule-1Pathogenesis of thromboembolismInstitutional review board approvalChest CT angiographyAdhesion molecule-1Endothelial cell adhesion molecule-1Novel therapeutic strategiesSodium citrate tubesReview board approvalClassical complement pathwayRadiologic confirmationICU patientsLiver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.Peer-Reviewed Original ResearchConceptsLiver sinusoidal endothelial cellsLiver injuryInterleukin-6Sinusoidal endothelial cellsAlanine aminotransferaseLiver histologyD-dimerCOVID-19Primary human liver sinusoidal endothelial cellsSARS-CoV-2 infectionHuman liver sinusoidal endothelial cellsEndothelial cellsSoluble glycoprotein 130IL-6 levelsSmall-interfering RNA knockdownJAK inhibitor ruxolitinibFactor VIII activityProinflammatory factorsInflammatory signalsLarge cohortInhibitor ruxolitinibVWF antigenEndotheliopathyPatientsInjuryPRO-THROMBOTIC SIGNATURE FROM NEUTROPHIL ACTIVATION AND DECREASED ADAMTS13 TO VWF RATIO IS A KEY DRIVER OF CARDIAC INJURY IN HOSPITALIZED PATIENTS WITH COVID-19
Wang S, Pine A, Mankbadi M, Chang C, Madeeva D, Zhang H, Dajani A, Crandall I, Sugeng L, Lee A, Chun H. PRO-THROMBOTIC SIGNATURE FROM NEUTROPHIL ACTIVATION AND DECREASED ADAMTS13 TO VWF RATIO IS A KEY DRIVER OF CARDIAC INJURY IN HOSPITALIZED PATIENTS WITH COVID-19. Journal Of The American College Of Cardiology 2021, 77: 3193. PMID: 34167644, PMCID: PMC8091195, DOI: 10.1016/s0735-1097(21)04548-4.Peer-Reviewed Original Research
2020
Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Durani U, Manana A, May J, Nelson M, Zheng Z, Gollapudi A, Alam S, Reynolds R, Thompson J, Kumbamu A, Das D, Murphy M, Henry E, Lee A, Marshall A, Wun T, Weeks L. Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. Blood 2020, 136: 20-21. PMCID: PMC8330314, DOI: 10.1182/blood-2020-143347.Peer-Reviewed Original ResearchMental health resourcesCOVID-19Health resourcesMental healthPrivate practiceImmune-compromised patientsLow patient volumeAmerican SocietyCOVID-19 pandemicPrevalence of burnoutMost respondentsPatient care responsibilitiesOverall cohortPercent of respondentsClinical careClinical OncologyPatient volumeNon-clinical workPrevalence variedMajority of traineesFellow experienceTrainee researchReduced motivationRespondent demographicsAdmission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.Peer-Reviewed Original ResearchIntermediate-dose anticoagulationAnti-platelet therapyAnticoagulation cohortOverall cohortMultivariable regression modelingRothman IndexDose anticoagulationHospital deathD-dimerPropensity scoreHospitalized patientsMechanical ventilationClinical trialsCOVID-19Prophylactic-dose anticoagulationRisk-stratified algorithmUse of aspirinChronic kidney diseasePropensity-Matched AnalysisEfficacy of aspirinSeverity of illnessAnti-platelet agentsMulti-site cohortImpact of aspirinSmall vessel thrombosisVWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
Madeeva D, Christian J, Goshua G, Chun H, Lee A, Pine A. VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study. Blood 2020, 136: 34-35. PMCID: PMC8330245, DOI: 10.1182/blood-2020-142917.Peer-Reviewed Original ResearchVWF/ADAMTS13 ratioVon Willebrand factorADAMTS13 ratioVenous thrombosisNeutrophil activationCOVID-19Severe COVID-19 diseaseVWF activityNon-ICU unitsPathogenesis of coagulopathySeverity of coagulopathyAbsolute neutrophil countInstitutional review board approvalMarkers of inflammationIntensive care unitCross-sectional studyPotential therapeutic targetSodium citrate tubesReview board approvalSignificant correlationCOVID-19 diseasePossible mechanistic linkImmune system effectorsNeutrophil indexPertinent patient informationEndotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patients